Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia (HAB)
|ClinicalTrials.gov Identifier: NCT01902602|
Recruitment Status : Unknown
Verified August 2013 by Herrmann Apparatebau GmbH.
Recruitment status was: Not yet recruiting
First Posted : July 18, 2013
Last Update Posted : August 13, 2013
The objective of this clinical study is to evaluate the influence of the Great autohemotherapy with oxygen-ozone (hyperbaric ozone therapy ) to describe the cardiovascular system in patients with resistant hypertension. The primary endpoint is the change in mean blood pressure after 10 treatments .
In addition, data are collected on the immune system as well as for food and sleep quality.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||March 2014|
|Estimated Study Completion Date :||June 2014|
- Change of blood pressure [ Time Frame: 3 months ]Primary endpoint is, that there is a changing of the middle blood pressure after 10 treatments. The blood pressure will get messured at all patients which get treated with oxygen-ozone. The aim is reached, if there is a reduction of the middle blood pressure after 10 treatments by 10 mmHg compared to the blood pressure by the patients at the baseline at beginning.
- Change of pulse [ Time Frame: 3 months ]The Pulse will be measured at each follow-up. It will be measured 3 times at the dominate arm.
- Change of blood count, liver and nephrew values [ Time Frame: 3 months ]The change of blood counts, liver and nephrew values serves as a sign for change of immune activity in a patient. Furthermore potential negative effects will be reportet as an adverse event.
- Change of liver and nephrew values [ Time Frame: 3 months ]
- Change of life and Sleeping quality [ Time Frame: 3 months ]Change of life and sleeping quality will be measured in a 7 scale. This questionnaire is to fill in by the patient.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01902602
|Dr. Panos Porikis||Recruiting|
|Biblis, Hessen, Germany, 68647|
|Contact: Panos Porikis, Phd +49 6245 8698 Dr.Porikis@t-online.de|
|Principal Investigator: Panos Porikis, Phd|
|Principal Investigator:||Panos Porikis, Phd||unafflicated|